Teleflex FY2025 EPS Forecast Increased by Wolfe Research

Teleflex Incorporated (NYSE:TFX) – Investment analysts at Wolfe Research lifted their FY2025 earnings per share estimates for shares of Teleflex in a report issued on Wednesday, November 12th. Wolfe Research analyst M. Polark now forecasts that the medical technology company will post earnings of $14.12 per share for the year, up from their prior estimate of $14.08. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Wolfe Research also issued estimates for Teleflex’s Q1 2026 earnings at $2.95 EPS, Q2 2026 earnings at $3.59 EPS, Q3 2026 earnings at $4.13 EPS, Q4 2026 earnings at $4.31 EPS, FY2026 earnings at $14.97 EPS, Q1 2027 earnings at $3.37 EPS, Q2 2027 earnings at $4.07 EPS, Q3 2027 earnings at $4.66 EPS, FY2027 earnings at $16.93 EPS and FY2028 earnings at $19.03 EPS.

Several other equities research analysts have also commented on TFX. Mizuho boosted their target price on shares of Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a research report on Friday, August 1st. Wall Street Zen lowered shares of Teleflex from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 15th. Wells Fargo & Company lowered their price target on Teleflex from $131.00 to $114.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Teleflex in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada lowered their price objective on shares of Teleflex from $135.00 to $120.00 and set a “sector perform” rating on the stock in a research note on Friday, November 7th. One analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $134.57.

Teleflex Trading Down 1.8%

Shares of TFX stock opened at $109.47 on Friday. The business’s fifty day moving average price is $124.31 and its 200 day moving average price is $122.48. The firm has a market capitalization of $4.84 billion, a PE ratio of 25.76, a P/E/G ratio of 1.79 and a beta of 1.05. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. Teleflex has a 1-year low of $102.58 and a 1-year high of $195.47.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, November 6th. The medical technology company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.38 by $0.29. The business had revenue of $892.90 million during the quarter, compared to the consensus estimate of $892.79 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The company’s revenue for the quarter was up 19.4% on a year-over-year basis. During the same period in the prior year, the business posted $3.49 EPS. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 15th. Investors of record on Friday, November 14th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $1.36 annualized dividend and a dividend yield of 1.2%. Teleflex’s dividend payout ratio is presently -18.50%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. NorthRock Partners LLC purchased a new position in shares of Teleflex during the 3rd quarter worth $333,000. Comerica Bank grew its position in shares of Teleflex by 106.6% in the third quarter. Comerica Bank now owns 32,844 shares of the medical technology company’s stock valued at $4,019,000 after purchasing an additional 16,948 shares during the period. Perbak Capital Partners LLP acquired a new position in Teleflex in the third quarter valued at $205,000. Glenmede Investment Management LP lifted its position in Teleflex by 9.8% during the third quarter. Glenmede Investment Management LP now owns 5,469 shares of the medical technology company’s stock worth $669,000 after buying an additional 488 shares during the period. Finally, Boston Partners lifted its position in Teleflex by 60.9% during the third quarter. Boston Partners now owns 612,898 shares of the medical technology company’s stock worth $75,000,000 after buying an additional 231,965 shares during the period. 95.62% of the stock is currently owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.